russjcardiolРоссийский кардиологический журналRussian Journal of Cardiology1560-40712618-7620«SILICEA-POLIGRAF» LLCrussjcardiol-1776Research ArticleКЛИНИКА И ФАРМАКОТЕРАПИЯGUIDELINES FOR THE PRACTITIONERЭФФЕКТИВНОСТЬ НЕЛИПОФИЛЬНЫХ ИНГИБИТОРОВ АНГИОТЕНЗИН-ПРЕВРАЩАЮЩЕГО ФЕРМЕНТА В ЛЕЧЕНИИ СЕРДЕЧНО-СОСУДИСТЫХ ЗАБОЛЕВАНИЙEFFICACY OF A NON-LIPOPHILIC ANGIOTENSIN CONVERTING ENZYME INHIBITOR AND ITS POSSIBLE ADVANTAGESМазурН. А.MazurN. A.Российская медицинская академия постдипломного образования, МоскваRussian Federation200328082003047679Copyright © Мазур Н.А., 20032003Мазур Н.А.Mazur N.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://russjcardiol.elpub.ru/jour/article/view/1776

Эффективность нелипофильных ингибиторов ангиотензин-превращающего фермента в лечении сердечно-сосудистых заболеваний.

Efficacy of a non-lipophilic angiotensin converting enzyme inhibitor and its possible advantages.

ReferencesCampbell D.J., Kladis A., Duncan A.M. Effects of converting enzyme inhibitors on angiotensin and bradykinin peptides. Hypertens. 1994; 23: 439-49.Campbell D.J., Kladis A., Duncan A.M. Effects of converting enzyme inhibitors on angiotensin and bradykinin peptides. Hypertens. 1994; 23: 439-49.Yesil S., Yesil M., Bayata S., Postaci N. ACE inhibitors and lough. Angiology 1994; 45(9): 805-8.Yesil S., Yesil M., Bayata S., Postaci N. ACE inhibitors and lough. Angiology 1994; 45(9): 805-8.Lancaster S.G., Todd P.A. Lisinopril: a preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in hypertension and congestive heart failure. Drugs 1988; 35: 646-69.Lancaster S.G., Todd P.A. Lisinopril: a preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in hypertension and congestive heart failure. Drugs 1988; 35: 646-69.Gissi-3 Investigators Six-month effects of early treatment with lisinopril and transdermal glyceryl trinitrate singly and together withdrawn six weeks after acate myocardial infarction: the Gissi-3 trial. J. Am. Coll Cardiol. 1996; 27: 337-44.Gissi-3 Investigators Six-month effects of early treatment with lisinopril and transdermal glyceryl trinitrate singly and together withdrawn six weeks after acate myocardial infarction: the Gissi-3 trial. J. Am. Coll Cardiol. 1996; 27: 337-44.Packer M., Poole-Wilson P.A., Armstrong P., et al. Comperative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. Circulation. 1999; 100: 1-7.Packer M., Poole-Wilson P.A., Armstrong P., et al. Comperative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. Circulation. 1999; 100: 1-7.Hansson L., Lindholm L.H., Ekbom T., et al. Randomised trial of old and new antihypertensive drugs in eldery patients: cardiovascular mortality and morbility the Swidish Trial in Old Patients with Hypertension-2 Study. Lancet. 1999: 354: 1751-6.Hansson L., Lindholm L.H., Ekbom T., et al. Randomised trial of old and new antihypertensive drugs in eldery patients: cardiovascular mortality and morbility the Swidish Trial in Old Patients with Hypertension-2 Study. Lancet. 1999: 354: 1751-6.ALLHAT Authors. Major Outcomes in High-Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme inhibitor or Calcium channel blocker VS Diuretic. JAMA. 2002 Dec 18; 288(23): 2981-97.ALLHAT Authors. Major Outcomes in High-Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme inhibitor or Calcium channel blocker VS Diuretic. JAMA. 2002 Dec 18; 288(23): 2981-97.Laviades C., Mayor G., Diez J. Treatment with lisinopril normalizes serum concentrations of procollagen type III amineterminal peptide in patients with essential hypertension. Am. J. Hypertens. 1994; 7(1): 52-8.Laviades C., Mayor G., Diez J. Treatment with lisinopril normalizes serum concentrations of procollagen type III amineterminal peptide in patients with essential hypertension. Am. J. Hypertens. 1994; 7(1): 52-8.TROPHY study Group. Lisinopril versus HCTZ in obese hypertensive patients: a multicenter placebo-controlled trial. Hypertens. 1997; 30: 140-45.TROPHY study Group. Lisinopril versus HCTZ in obese hypertensive patients: a multicenter placebo-controlled trial. Hypertens. 1997; 30: 140-45.EUCLID study Group. Randomized placebo controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. Lancet. 1997; 349: 1787-92.EUCLID study Group. Randomized placebo controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. Lancet. 1997; 349: 1787-92.

The authors declare that there are no conflicts of interest present.